Dr. Jeffrey Gladden argues that amyloid-clearing antibodies fail because they treat a symptom, not the cause. Infections hijack mitochondria and trigger inflammation, so removing amyloid plaques is like silencing a smoke detector while the fire burns. He calls for better infection testing and phage therapy instead.
One of the reasons why I believe that the amyloid-clearing antibodies are not demonstrating a whole lot of efficacy, it's that it's there for a reason. It's not to say it's not problematic, it is, but what happens even if you took away the amyloid, and from the research that's already been published, if you have a confluence of organisms that by nature of being alive, they have to steal energy from your mitochondria, they have to dysregulate metals, lipids, they have to drive oxidative stress as a part of their whole thing, right? They cause the release of heat shock proteins and cytokines. You haven't actually handled, you've taken the batteries out of the smoke detector while the fire is raging. So the drug situation has undoubtedly delayed progress because, you know, and I, I worked in pharma and biotech. I'm not against drug development. We need innovation. We need people that are actually creating solutions to the problems. We need better testing for infections is one great example. We need better precise treatments, things like phage therapy that could potentially have promise to be more widespread use someday.
